Insulin Market in China 2014-2018

中国のインスリン製品市場

◆タイトル:Insulin Market in China 2014-2018
◆商品コード:IRTNTR4464
◆調査・発行会社:Technavio (Infiniti Research Ltd.)
◆発行日:2014年10月22日
◆ページ数:78
◆資料形式:pdf / 英語
◆納品方法:Eメール
◆調査対象地域:中国
◆産業分野:医療
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥267,500見積依頼/購入/質問フォーム
Five UserUSD2,800 ⇒換算¥299,600見積依頼/購入/質問フォーム
Enterprise License(社内共有可)USD3,500 ⇒換算¥374,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、資料に記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はTechnavio (Infiniti Research Ltd.)の日本における正規販売代理店です。

【資料の概要】

本調査レポートでは、"中国のインスリン製品市場"について調査・分析し、エグゼクティブサマリー、市場概観、市場規模及び予測、種類別分析、市場シェア、購買基準、市場成長要因、市場の課題、市場動向、競争状況、主要企業(ベンダー)分析等の情報をお届けいたします。

About Insulin
Insulin is a hormone produced in the pancreas. It regulates the metabolism of glucose and other nutrients in the body. Insulin permits the body to utilize sugar (glucose) from carbohydrates in the food for energy or to store glucose for future use. Various types of insulin exist depending on how quickly they work, when they peak, and how long they last. In diabetic condition, the pancreas no longer produces adequate insulin or the cells stop responding to the insulin that is produced, leading to rise in blood glucose level.

TechNavio’s analysts forecast the Insulin market in China to grow at a CAGR of 15.57 percent over the period 2013-2018.

[Covered in this Report]
The Insulin market in China can be divided into two segments: Recombinant Insulin and Modern Insulin. This report covers the present scenario and the growth prospects of the Insulin market in China for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sales of various second and third generation insulin products.

TechNavio’s report, Insulin Market in China 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Insulin market landscape in China and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.

[Key Vendors]
• Eli Lilly
• Novo Nordisk
• Sanofi
• Tonghua Dongbao Pharmaceutical

Other Prominent Vendors• Abbott Laboratories
• Bayer Healthcare
• Biocon
• Boehringer Ingelheim
• Gan & Lee Pharmaceutical
• Glenmark Pharmaceuticals
• Jiangsu Wanbang Biopharmaceuticals
• Merck
• Mylan
• Pfizer
• Piramal Healthcare
• SciGen
• Shanghai Fosun Pharmaceutical
• Shenzhen Kexing Biotech
• Wangbang Pharma Group
• Wockhardt
• Yabao Pharmaceutical
• Zhuhai United Laboratories

[Market Driver]
• Increase in Diabetic Population
• For a full, detailed list, view our report

[Market Challenge]
• High Cost of Insulin
• For a full, detailed list, view our report

[Market Trend]
• Increase in Strategic Alliances among Vendors
• For a full, detailed list, view our report

[Key Questions Answered in this Report]
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

【資料の目次】

01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Rate of Incidence and Prevalence
07.1.1 Diabetes
08. Market Segmentation by Type
08.1 Recombinant Insulin Market in China
08.1.1 Market Size and Forecast
08.2 Modern Insulin Market in China
08.2.1 Market Size and Forecast
09. Market Assessment of Top Drugs
09.1 Lantus
09.1.1 Sales
09.2 Apidra
09.2.1 Sales
09.3 Insuman
09.3.1 Sales
09.4 Novorapid/Novolog
09.4.1 Sales
09.5 Levemir
09.5.1 Sales
09.6 Novomix/Nologmix
09.6.1 Sales
09.7 Humulin
09.7.1 Sales
09.8 Humalog
09.8.1 Sales
10. Buying Criteria
11. Market Growth Drivers
12. Drivers and their Impact
13. Market Challenges
14. Impact of Drivers and Challenges
15. Market Trends
16. Trends and their Impact
17. Vendor Landscape
17.1 Competitive Scenario
17.1.1 Key News
17.2 Market Share Analysis 2013
17.2.1 Other Prominent Vendors
18. Key Vendor Analysis
18.1 Eli Lilly
18.1.1 Key Facts
18.1.2 Business Overview
18.1.3 Business Segmentation by Revenue 2013
18.1.4 Business Segmentation by Revenue 2012 and 2013
18.1.5 Sales by Geography
18.1.6 Business Strategy
18.1.7 Key Developments
18.1.8 SWOT Analysis
18.2 Novo Nordisk A/S
18.2.1 Key Facts
18.2.2 Business Overview
18.2.3 Business Segmentation
18.2.4 Business Strategy
18.2.5 Revenue Segmentation by Business
18.2.6 Revenue Comparison by Business Segments 2012 and 2013
18.2.7 Sales by Geography
18.2.8 Key Information
18.2.9 SWOT Analysis
18.3 Sanofi
18.3.1 Key Facts
18.3.2 Business Overview
18.3.3 Business Segmentation by Revenue 2013
18.3.4 Business Segmentation by Revenue 2012 and 2013
18.3.5 Geographical Segmentation by Revenue 2013
18.3.6 Business Strategy
18.3.7 Key Developments
18.3.8 SWOT Analysis
18.4 Tonghua Dongbao Pharmaceutical
18.4.1 Key Facts
18.4.2 Business Overview
18.4.3 Business Segmentation by Revenue 2013
18.4.4 Business Segmentation by Revenue 2012 and 2013
18.4.5 Geographical Segmentation by Revenue 2013
18.4.6 Recent Developments
18.4.7 SWOT Analysis
19. Other Reports in this Series

[List of Exhibits]
Exhibit 1: Market Research Methodology
Exhibit 2: Insulin Market in China 2013-2018 (US$ billion)
Exhibit 3: Insulin Market in China Market Segmentation by Type
Exhibit 4: Insulin Market in China Market Segmentation by Type 2013
Exhibit 5: Modern Insulin Segmentation by Volume in China 2013
Exhibit 6: Onset and Duration of Recombinant Insulin
Exhibit 7: Recombinant Insulin Market in China 2013-2018 (US$ billion)
Exhibit 8: Modern Insulin Market in China 2013-2018 (US$ billion)
Exhibit 9: Sanofi’s Lantus Revenue 2010-2013 (US$ million)
Exhibit 10: Sanofi’s Apidra Revenue 2010-2012 (US$ million)
Exhibit 11: Sanofi’s Insuman Revenue 2010-2012 (US$ million)
Exhibit 12: Novo Nordisk’s Novorapid/Novolog Revenue 2010-2013 (US$ million)
Exhibit 13: Novo Nordisk’s Levemir Revenue 2010-2013 (US$ million)
Exhibit 14: Novo Nordisk’s Novomix/Nologmix Revenue 2010-2013 (US$ million)
Exhibit 15: Eli Lilly’s Humulin Revenue 2011-2013 (US$ million)
Exhibit 16: Eli Lilly’s Humalog Revenue 2011-2013 (US$ million)
Exhibit 17: Global Prevalence of Diabetes 2013
Exhibit 18: No. of People with Diabetes according to IDF 2030
Exhibit 19: Increase in Diabetic Population in China in million
Exhibit 20: Insulin Market in China Market Share Analysis 2013
Exhibit 21: Insulin Market in China Market Share Analysis by Volume 2013
Exhibit 22: Revenue Share of Novo Nordisk’s Insulin Products (in Percent)
Exhibit 23: Novo Nordisk’s Insulin Products Revenue Segmentation by Geography (in Percentage)
Exhibit 24: Geography Wise Revenue of Novo Nordisk’s Insulin Products (US$ million)
Exhibit 25: Revenue of Novo Nordisk’s Insulin Products in China (US$ million)
Exhibit 26: Sanofi’s Insulin Products Revenue Segmentation by Geography (in Percentage)
Exhibit 27: Eli Lilly’s Insulin Products Revenue Segmentation by Geography (in Percentage)
Exhibit 28: Geography Wise Revenue of Eli Lilly’s Insulin Products (US$ million)
Exhibit 29: Eli Lilly and Co.: Business Segmentation by Revenue 2013
Exhibit 30: Eli Lilly and Co.: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 31: Eli Lilly and Co.: Sales by Geography 2013
Exhibit 32: Business Segments of Novo Nordisk A/S 2013
Exhibit 33: Novo Nordisk A/S: Business Segmentation 2013
Exhibit 34: Novo Nordisk A/S: Revenue Comparison 2012 and 2013 (US$ million)
Exhibit 35: Novo Nordisk A/S: Sales by Geography 2013
Exhibit 36: Sanofi: Business Segmentation by Revenue 2013
Exhibit 37: Sanofi: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 38: Sanofi: Geographical Segmentation by Revenue 2013
Exhibit 39: Tonghua Dongbao Pharmaceutical: Business Segmentation by Revenue 2013
Exhibit 40: Tonghua Dongbao Pharmaceutical: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 41: Tonghua Dongbao Pharmaceutical: Geographical Segmentation by Revenue 2013



【掲載企業】

Eli Lilly,Novo Nordisk ,Sanofi,Tonghua Dongbao Pharmaceutical ,Abbott Laboratories ,Bayer Healthcare ,Biocon ,Boehringer Ingelheim ,Gan & Lee Pharmaceutical ,Glenmark Pharmaceuticals ,Jiangsu Wanbang Biopharmaceuticals ,Merck ,Mylan ,Pfizer ,Piramal Healthcare ,SciGen,Shanghai Fosun Pharmaceutical ,Shenzhen Kexing Biotech,Wangbang Pharma Group,Wockhardt,Yabao Pharmaceutical ,Zhuhai United Laboratories

【資料のキーワード】

インスリン、組み換えインスリン、モダンインスリン

【調査方法】

一次資料による調査(業界専門家、ベンダー、代理店、顧客等を対象にしたデプスインタビュー調査など)及び二次資料による調査(Technavio独自のプラットフォーム、産業書籍、企業報告書、ニュース記事、アナリストレポート、貿易協会、政府機関発行データなど)

★調査レポート[中国のインスリン製品市場] (Insulin Market in China 2014-2018 / IRTNTR4464)販売に関する免責事項
[中国のインスリン製品市場] (Insulin Market in China 2014-2018 / IRTNTR4464)についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆